Skip to main content
×
×
Home

Assessing the Impact of Field-of-Use Restrictions in Patent Licensing Agreements: The Ethical Pharmaceutical Industry in the United States, 1950–1962

  • MAR CEBRIÁN VILLAR (a1) and SANTIAGO LÓPEZ GARCÍA (a2)
Abstract

There are a number of strategies employed by companies to limit price competition, including patenting. This article investigates patent licensing restrictions as a strategy to erode price competition, using mainly information gleaned from the 1960–1962 Kefauver Committee hearings. The article deals with the pharmaceutical industry, which is one of the few sectors in which patents are essential to the development and introduction of innovations. The current study adds to a body of literature that has yielded mixed results with respect to the role of patents in this industry. The main contribution of this research is that restrictive licensing clauses, specifically field-of-use restrictions, are found to be relevant in eroding price competition in the institutional market. However, in the retail ethical market, price competition was absent even when no field-of-use restrictions were included in licensing contracts, although product competition was relevant between patented drugs.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Assessing the Impact of Field-of-Use Restrictions in Patent Licensing Agreements: The Ethical Pharmaceutical Industry in the United States, 1950–1962
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Assessing the Impact of Field-of-Use Restrictions in Patent Licensing Agreements: The Ethical Pharmaceutical Industry in the United States, 1950–1962
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Assessing the Impact of Field-of-Use Restrictions in Patent Licensing Agreements: The Ethical Pharmaceutical Industry in the United States, 1950–1962
      Available formats
      ×
Copyright
References
Hide All
Boldrin, Michele, and Levine, David K.. Against Intellectual Monopoly. Cambridge: Cambridge University Press, 2008.
Carpenter, Daniel. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, NJ: Princeton University Press, 2010.
Chandler, Alfred D. Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries. Cambridge, MA: Harvard University Press, 2005.
Contractor, Farok J. Licensing in International Strategy. Westport, CT: Quorum Books, 1985.
Gambardella, Alfonso. Science and Innovation: The US Pharmaceutical Industry During the 1980s. Cambridge: Cambridge University Press, 1995.
Gaudillière, Jean Paul, and Thoms, Ulrike. The Development of Scientific Marketing in the Twentieth Century: Research for Sales in the Pharmaceutical Industry. London: Routledge, 2015.
Greene, Jeremy A. Generic: The Unbranding of Modern Medicine. Baltimore, MD: The Johns Hopkins University Press, 2014.
Greene, Jeremy A. Prescribing by Numbers: Drugs and the Definitions of Disease. Baltimore, MD: The Johns Hopkins Press, 2007.
Greene, Jeremy A., and Siegel Watkins, E., eds. Prescribed: Writing, Filling, Using, and Abusing the Prescription in Modern America. Baltimore, MD: The Johns Hopkins University Press, 2012.
Harris, Richard. The Real Voice. New York: Macmillan, 1964.
Healy, David. The Antidepressant Era. Cambridge, MA: Harvard University Press, 1997.
Healy, David. The Creation of Psychopharmacology. Cambridge, MA: Harvard University Press, 2002.
Healy, David. Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. New York: New York University Press, 2004.
Herzberg, David. Happy Pills in America: From Miltown to Prozac. Baltimore, MD: The Johns Hopkins University Press, 2009.
Liebenau, Jonathan. Medical Science and Medical Industry: The Formation of the American Pharmaceutical Industry. Baltimore, MD: The Johns Hopkins University Press, 1987.
Mahoney, Tom. The Merchants of Life. New York: Harper and Brothers, 1959.
Marks, Harry M. Progress of Experiment: Science and Therapeutic Reform in the United States, 1900–1990. Cambridge: Cambridge University Press, 1997.
Metzl, Jonathan. Prozac on the Couch: Prescribing Gender in the Era of Wonder Drugs. Durham, NC: Duke University Press, 2003.
Mintz, Morton. The Therapeutic Nightmare. Boston, MA: Houghton Mifflin, 1965.
Rasmussen, Nicolas. On Speed: The Many Lives of Amphetamine. New York: New York University Press, 2008.
Schwartzman, David. Innovation in the Pharmaceutical Industry. Baltimore, MD: The Johns Hopkins University Press, 1976.
Shorter, Edward. A History of Psychiatry: From the Era of the Asylum to the Age of Prozac. Oxford: John Wiley & Sons, 1997.
Silberston, Zangwill Aubrey. The Economic Importance of Patents. London: Common Law Institute of Intellectual Property, 1987.
Silverman, Milton. The Drugging of the Americas. Berkeley: University of California Press, 1976.
Silverman, Milton, and Lee, Philip R.. Pills, Profits & Politics. Berkeley: University of California Press, 1974.
Smith, Mickey C. A Social History of the Minor Tranquilizers: The Quest for Small Comfort in the Age of Anxiety. Santa Barbara, CA: Greenwood Publishing Group, 1991.
Swazey, Judith. Chlorpromazine in Psychiatry: A Study of Therapeutic Innovation. Cambridge, MA: MIT Press, 1974.
Taylor, Christopher T., and Aubrey Silberston, Z.. The Economic Impact of the Patent System. Cambridge: Cambridge University Press, 1973.
Temin, Peter. Taking Your Medicine: Drug Regulation in the United States. Cambridge, MA: Harvard University Press, 1980.
Tobbell, Dominique. Pills, Power, and Policy: The Struggle for Drug Reform in Cold War America and Its Consequences. Berkeley: University of California Press/Milbank Books on Health and the Public, 2012.
Tone, Andrea. The Age of Anxiety: A History of America’s Turbulent Affair with Tranquilizers. New York: Basic Books, 2009.
Williamson, James R. Federal Antitrust Policy during the Kennedy–Johnson Years. Westport, CT: Praeger Publishers, 1995.
Achilladelis, Basil, and Antonakis, Nicholas. “The Dynamics of Technological Innovation: The Case of the Pharmaceutical Industry.” Research Policy 30 (2001): 535588.
Arora, Ashish. “Patents, Licensing, and Market Structure in the Chemical Industry.” Research Policy 26, no. 4 (1997): 391403.
Arrow, Kenneth J. “Economic Welfare and the Allocation of Resources for Invention.” In The Rate and Direction of Inventive Activity: Economic and Social Factors, edited by Universities-National Bureau Committee for Economic Research, Committee on Economic Growth of the Social Science Research Council, 609626. Princeton, NJ: Princeton University Press, 1962.
Bachrach, Leona L. “The State of the State Mental Hospital at the Turn of the Century.” New Directions for Mental Health Services 91 (2001): 89106.
Ban Thomas, A. “Fifty Years Chlorpromazine: A Historical Perspective.” Neuropsychiatric Disease & Treatment 3, no. 4 (2007): 495500.
Bud, Robert. “Antibiotics, Big Business, and Consumers: The Context of Government Investigations Into the Postwar American Drug Industry.” Technology and Culture 46, no. 2 (2005): 329349.
Clarkson, Kenneth W. “The Use of Pharmaceutical Profitability Measures for Public Policy Actions.” In Issues in Pharmaceutical Economics, edited by Chien, Robert L., 105124. Lexington, MA: Lexington Books, 1979.
Comanor, William S. “Research and Competitive Product Differentiation in the Pharmaceutical Industry in the United States.” Economica 31, no. 124 (1964): 372384.
Comanor, William S. “The Political Economy of the Pharmaceutical Industry.” Journal of Economic Literature 24 (September 1986): 11781217.
David, Paul, Foray, Dominique, and Edward Steinmueller, W.. “The Research Network and the New Economics of Science: From Metaphor to Organizational Behaviours.” In The Organization of Economic Innovation in Europe, edited by Gambardella, A. and Malerba, F., 303342. Cambridge: Cambridge University Press, 1999.
Donohue, Julie. “History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection.” Milbank Quarterly 84, no. 4 (2006): 659699.
Ellison, Glenn, and Ellison, Sara F.. “Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration.” American Economic Journal: Microeconomics 3, no. 1 (2011): 136.
Faunce, T., and Lexchin, J.. “‘Linkage’ Pharmaceutical Evergreening in Canada and Australia.” Australia and New Zealand Health Policy 4, no. 8 (2007): 111.
Gallini, Nancy. “Deterrence by Market Sharing: A Strategic Incentive for Licensing.” American Economic Review 74 (1984): 931941.
Gallini, Nancy. “The Economics of Patents: Lessons from Recent US Patent Reform.” Journal of Economic Perspectives 16, no. 2 (2002): 131154.
Gaudillière, Jean Paul. “From Propaganda to Scientific Marketing: Schering, Cortisone, and the Construction of Drug Markets.” History and Technology 29, no. 2 (2013): 188209.
Gaudillière, Jean Paul. “Marketing Loops: Clinical Research, Consumption of Antidepressants and the Reorganization of Promotion at Geigy in the 1960s and 1970s.” In The Development of Scientific Marketing in the Twentieth Century: Research for Sales in the Pharmaceutical Industry, edited by Gaudillière, Jean Paul and Thoms, Ulrike, 167190. London: Routledge, 2015.
Grabowski, Henry G., and Vernon, John M.. “Substitution Laws and Innovation in the Pharmaceutical Industry.” Law Contemporary Problems 43, no. 1 (Winter–Spring 1979): 4366.
Greene, Jeremy A. “Attention to ‘Details’: Etiquette and the Pharmaceutical Salesman in Postwar American.” Social Studies of Science 34, no. 2 (2004): 271292.
Greene, Jeremy A., and Podolsky, Scott H.. “Keeping Modern in Medicine: Pharmaceutical Promotion and Physician Education in Postwar America.” Bulletin of the History of Medicine 83, no. 2 (2009): 331377.
Greene, Jeremy A., and Podolsky, Scott H.. “Reform, Regulation, and Pharmaceuticals—The Kefauver-Harris Amendments at 50.” New England Journal of Medicine 367 (2012): 14811483.
Gronfein, William. “Psychotropic Drugs and the Origins of Deinstitutionalization.” Social Problems 32, no. 5 (1985): 437454.
Harcourt, Bernard E. “Reducing Mass Incarceration: Lessons from the Deinstitutionalization of Mental Hospitals in the 1960s.” Ohio State Journal of Criminal Law 53 (2011): 5388.
Henderson, R., Orsenigo, L., and Pisano, G. P.. “The Pharmaceutical Industry and the Revolution in Molecular Biology: Exploring the Interaction between Scientific, Institutional and Organizational Change.” In The Sources of Industrial Leadership, edited by Mowery, D. and Nelson, R. R., 267311. Cambridge: Cambridge University Press, 1999.
Herzberg, David. “Busted for Blockbusters. ‘Scrip Mills?’ Quaalude, and Prescribing Power in the 1970s.” In Prescribed: Writing, Filling, Using, and Abusing the Prescription in Modern America, edited by Greene, Jeremy A. and Siegel, E., 207231. Watkins. Baltimore, MD: The Johns Hopkins University Press, 2012.
Ignaciuk, Agata, Ortiz-Gómez, Teresa, and Rodriguez-Ocaña, Esteban. “Doctors, Women and the Circulation of Knowledge of Oral Contraceptives in Spain, 1960s–1970s.” In Gendered Drugs and Medicine: Historical and Socio-Cultural Perspectives, edited by Ortiz-Gómez, Teresa and Santesmases, María Jesús, 133152. Burlington, VT: Ashgate Publishing, 2014.
Katz, Michael L., and Shapiro, Carl. “How to License Intangible Property.” Quarterly Journal of Economics 101 (1986): 567589.
Kendall, K. W., Ng, Simon, and Schoner, Bertram. “Consumer Responses to Generic/Chemically Equivalent Drugs.” Journal of Public Policy and Marketing 10, no. 2 (1991): 182201.
Kessel, Nils. “Beyond Innovation: Pharmaceutical Marketing, Market Structure and the Importance of the Old in West Germany, 1950–70.” In The Development of Scientific Marketing in the Twentieth Century: Research for Sales in the Pharmaceutical Industry, edited by Gaudillière, Jean Paul and Thoms, Ulrike, 1528. London: Routledge, 2015.
Kessel, Nils. “‘Doriden von Ciba’: Sleeping Pills, Pharmaceutical Marketing, and Thalidomide, 1955–1963.” History and Technology 29, no. 2 (2013): 191205.
Kremer, Michael. “Patent Buyouts: Mechanisms for Encouraging Innovation.” Quarterly Journal of Economics 113, no. 4 (1998): 11371167.
Lall, Sanjaya. “International Pharmaceutical Industry and Less-Developed Countries: I: Oligopolistic Power of Leading Firms.” Economic and Political Weekly 9, no. 47 (1974): 19471958.
Lall, Sanjaya. “Price Competition and the International Pharmaceutical Industry.” Oxford Bulletin of Economics and Statistics 40 (1978): 921.
Lanjouw, Jean O., and Schankerman, Mark. “Protecting Intellectual Property Rights: Are Small Firms Handicapped?” Journal of Law and Economics 47 (2004): 4574.
Laties, Victor G., and Weiss, Bernard. “A Critical Review of the Efficacy of Meprobamate (Miltown, Equanil) in the Treatment of Anxiety.” Journal of Chronic Diseases 7, no. 6 (1978): 500519.
Lee, Thomas H. “Me-too Products: Friend or Foe?” New England Journal of Medicine 350 (2004): 211212.
Leffler, Keith B. “Persuasion or Information? The Economics of Prescription Drug Advertising.” Journal of Law and Economics 24 (1981): 4574.
Levin, Richard C., Klevorick, Alvin K., Nelson, Richard R., and Winter, Sidney G.. “Appropriating the Returns from Industrial Research and Development.” Brookings Papers on Economic Activity 3 (1987): 783832.
Liebenau, Jonathan. “Patents and the Chemical Industry: Tools of Business Strategy.” In The Challenge of New Technology: Innovation in British Business Since 1850, edited by Liebenau, Jonathan, 133150. Aldershot, UK: Gower, 1988.
López-Muñoz, Francisco, Alamo, Cecilio, Cuenca, Eduardo Shen, Clervoy, Patrick Winston W., and Rubio, Gabriel. “History of the Discovery and Clinical Introduction of Chlorpromazine.” Annals of Clinical Psychiatry 17, no. 3 (2005): 113135.
Mansfield, Edwin. “Patents and Innovation: An Empirical Study.” Management Science 32, no. 2 (1986): 173181.
Marks, Harry M. “Making Risks Visible: The Science, Politics and Regulation of Adverse Drug Reactions.” In Ways of Regulating: Therapeutic Agents Between Plants, Shops and Consulting Rooms, edited by Gaudillière, Jean Paul and Hess, Volker, 105122. Berlin, Germany: Max-Planck Institute, 2009.
Mechanic, David, and Rochefort, David A.. “Deinstitutionalization: An Appraisal of Reform.” Annual Review of Sociology 16 (1990): 301327.
Meurer, Michael J. “The Settlement of Patent Litigation.” RAND Journal of Economics 20, no. 1 (1989): 7791.
Munos, Bernard. “Lessons from 60 years of Pharmaceutical Innovation.” Nature Reviews Drug Discovery 8 (2009): 959968.
Penin, Julien. “Patents Versus Ex Post Rewards: A New Look.” Research Policy 34 (2005): 641–156.
Polanyi, Michael. “Patent Reform.” Review of Economic Review 11 (1944): 6176.
Quirke, Viviane. “The Material Culture of British Pharmaceutical Laboratories in the Golden Age of Drug Discovery (c. 1935–75).” International Journal for the History of Engineering & Technology 79, no. 2 (2009): 280299.
Quirke, Viviane. “From Alkaloids to Gene Therapy: A Brief History of Drug Discovery in the 20th Century.” In Making Medicines: A Brief History of Pharmacy and Pharmaceuticals, edited by Anderson, Stuart, 177201. London: Pharmaceutical Press, 2005.
Rasmussen, Nicolas. “Making the First Anti-Depressant: Amphetamine in American Medicine, 1929–1950.” Journal of the History of Medicine and Allied Sciences 61, no. 3 (2006): 288323.
Rockett, Katharine E. “Choosing the Competition and Patent Licensing.” RAND Journal of Economics 21, no. 1 (1990): 161171.
Sarett, Lewis H. “FDA Regulations and Their Influence on Future R and D.” Research Management 27 (March 1974): 1820.
Scroop, Daniel. “A Faded Passion? Estes Kefauver and the Senate Subcommittee on Antitrust and Monopoly.” Business and Economic History On-Line 5 (2007): 117.
Slinn, Judy. “The Development of the Pharmaceutical Industry.” In Making Medicines: A Brief History of Pharmacy and Pharmaceuticals, edited by Anderson, Stuart, 155176. London: Pharmaceutical Press, 2005.
Slinn, Judy. “Price Controls or Control Through Prices? Regulating the Cost and Consumption of Prescription Pharmaceuticals in the UK, 1948–67.” Business History 47, no. 3 (2005): 352366.
Slinn, Judy. “Patents and the UK Pharmaceutical Industry Between 1945 and the 1970s.” History and Technology 24, no. 2 (2008): 191205.
Statman, Meir. “The Effect of Patent Expiration on the Market Position of Drugs.” In Drugs and Health: Issues and Policy Objectives, edited by Helms, Robert B., 140151. Washington, DC: American Enterprise Institute, 1981.
Statman, Meir, and Tyebjee, Tyzoon. “Strategic Responses to Changes in Public Policy: The Case of the Pharmaceutical Industry and Drug Substitution Laws.” Journal of Public Policy and Marketing 3, no. 1 (1984): 99112.
Statman, Meir, and Tyebjee, Tyzoon. “Trademarks, Patents, and Innovation in the Ethical Drug Industry.” Journal of Marketing 45, no. 3 (1981): 7181.
Steele, Henry. “The Fortunes of Economic Reform Legislation: The Case of the Drug Amendments Act of 1962.” American Journal of Economics and Sociology 25, no. 1 (January 1966): 3951.
Steele, Henry. “Monopoly and Competition in the Ethical Drugs Market.” Journal of Law and Economics 5, no. 1 (1962): 131163.
Steele, Henry. “Patent Restrictions and Price Competition in the Ethical Drugs.” Journal of Industrial Economics 12, no. 3 (1964): 198223.
Stiglitz, Joseph E. “Give Prizes not Patents.” New Scientist 21 (September 16, 2006): 21.
Swann, John P. “FDA and the Practice of Pharmacy: Prescription Drug Regulation before the Durham–Humphrey Amendment of 1951.” Pharmacy in History 36, no. 2 (1994): 5570.
Temin, Peter. “The Origin of Compulsory Drug Prescription.” Journal of Law and Economics 22, no. 1 (1979a): 91105.
Temin, Peter. “Technology, Regulation, and Market Structure in the Modern Pharmaceutical Industry.” Bell Journal of Economics 10, no. 2 (1979): 427446.
Thoms, Ulrike. “The Contraceptive Pill, the Pharmaceutical Industry and Changes in the Patient–Doctor Relationship in West Germany.” In Gendered Drugs and Medicine: Historical and Socio-Cultural Perspectives, edited by Ortiz-Gómez, Teresa and Santesmases, María Jesús, 153176. Burlington, VT: Ashgate Publishing, 2014.
Thoms, Ulrike. “Standardizing Selling: Pharmaceutical Marketing, the Pharmaceutical Company and the Marketing Expert (1900–1980).” History and Technology 29, no. 2 (2013): 169187.
Tobbell, Dominique. “Allied Against Reform: Pharmaceutical Industry–Academic Physician Relations in the United States, 1945–1970.” Bulletin of the History of Medicine 82, no. 4 (2008): 878912.
Tobbell, Dominique. “Pharmaceutical Politics and Regulatory Reform in Postwar America.” In What’s Good for Business, edited by Fein, Kim Phillips and Zelizer, Julian E., 123139. Oxford: Oxford University Press, 2012.
Tobbell, Dominique. “‘Who’s Winning the Human Race?’ Cold War as Pharmaceutical Political Strategy.” Journal of the History of Medicine and Allied Sciences 64, no. 4 (2009): 429473.
Tone, Andrea. “Making of Miltown.” In The Age of Anxiety: A History of America’s Turbulent Affair with Tranquilizers, edited by Tone, Andrea, 2752. New York: Basic Books, 2009.
Tone, Andrea. “Tranquilizers on Trial: Psychopharmacology in the Age of Anxiety.” In Medicating Modern America: Prescription Drugs in History, edited by Tone, Andrea and Watkins, Elizabeth Siegel, 156180. New York: New York University Press, 2007.
Wright, Brian D. “The Economics of Invention Incentives: Patents, Prizes, and Research Contracts.” American Economic Review 73 (1983): 691707.
Bond, Ronald S., and David, F.. Lean Economic Report on Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets. Staff Report to the Federal Trade Commission, Bureau of Economics, 1977. https://www.ftc.gov/sites/default/files/documents/reports/sales-promotion-and-product-differentiation-two-prescription-drug-markets/197702salespromo.pdf.
McFadyen, Richard E. “Estes Kefauver and the Drug Industry.” Ph.D. diss., Emory University, 1973.
Moon, Nathan William. “The Amphetamine Years: A Study of the Medical Applications and Extramedical Consumption of Psychostimulant Drugs in the Postwar United States, 1945–1980.” Ph.D. diss., Georgia Institute of Technology, 2009.
United States Senate. “Administered Prices in the Drug Industry.” Hearings before the Subcommittee on Antitrust and Monopoly, Senate Committee on the Judiciary, 86th Congress, 2nd Session, Washington, DC, 1960.
United States Senate. “Administered Prices in the Drug Industry.” Report 448. Hearings before the Subcommittee on Antitrust and Monopoly, Senate on the Judiciary, 87th Congress, 1st session, Washington, DC, 1961.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Enterprise & Society
  • ISSN: 1467-2227
  • EISSN: 1467-2235
  • URL: /core/journals/enterprise-and-society
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 39
Total number of PDF views: 175 *
Loading metrics...

Abstract views

Total abstract views: 409 *
Loading metrics...

* Views captured on Cambridge Core between 20th February 2017 - 19th September 2018. This data will be updated every 24 hours.